Multiple Sclerosis Market, By Type (Primary progressive MS (PPMS), Secondary progressive MS (SPMS), Clinically isolated syndrome (CIS), and Relapse-remitting MS (RRMS)), By Drug Class (Interferons, Immunomodulators, Immunosuppressants, and Others), By Treatment (Physical Therapy, Medications, Plasma Exchange, and Stem Cell Therapy), By End-Users (Specialty Clinics, Homecare, Hospitals, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI518623 | Publish Date: March 2024 | No. of Pages: 189

Multiple Sclerosis Market Overview

Multiple Sclerosis Market was valued at US$ 22.5 Billion in 2024 and is projected to grow at a CAGR of 38% to reach US$ 422.1 Billion by 2034.

[PDF] Multiple sclerosis (MS) is a chronic and often disabling autoimmune disease that affects the central nervous system, which includes the brain and spinal cord. In MS, the immune system mistakenly attacks the protective covering of nerve fibers, called myelin, leading to inflammation, damage, and scar tissue formation. This damage disrupts the normal flow of electrical impulses along the nerves, causing a wide range of symptoms that can vary greatly from person to person. 

Multiple Sclerosis Market Dynamics

Increasing Prevalence

A higher prevalence of MS directly contributes to the growth of the MS market. With more individuals being diagnosed with the condition, there is a greater demand for treatments, medications, healthcare services, and support.

For instance, in July 2020, according to PLOS ONE report, based on record linking of national multiple healthcare administrative data, the sources determined the incidence and prevalence of multiple sclerosis in Hungary. The incidence rate of MS in Hungary is moderate, and the prevalence is higher than previously estimated. While the incidence rate is declining, the prevalence is increasing. The percentage of patients receiving disease-modifying therapy increased but remained at 30%.

Advancements in Research

Researchers are always trying to identify the precise causes and precipitating factors of MS. Genetic, environmental, and immunological variables are all being researched, but the exact cause is yet unknown. Strategies for preventing or controlling the disease could result from advancements in this field. Finding trustworthy MS biomarkers can help in early diagnosis, tracking the course of the illness, and customizing treatment regimens. To enhance patient care, researchers are investigating numerous blood, cerebrospinal fluid, and imaging markers.

Restrains:

High treatment costs can limit access to disease-modifying therapies (DMTs) and other essential treatments for individuals with MS. Some patients may be unable to afford these therapies, which can lead to unmet medical needs and poorer health outcomes. High treatment costs can exacerbate healthcare disparities, as individuals with limited financial means may face greater challenges in accessing and affording MS treatments. This can result in unequal access to care and disparities in health outcomes.    

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Multiple Sclerosis Market Segmentation

Multiple Sclerosis Market Segmentation:

Multiple Sclerosis Market is segmented based on Type, Drug Class, Treatment, End-Users and Region.

Type Insight

On the basis of Type, Multiple Sclerosis Market is segmented into Primary progressive MS (PPMS), Secondary progressive MS (SPMS), clinically isolated syndrome (CIS), and Relapse-remitting MS (RRMS).

Drug Class Insights

On the basis of Drug Class, Multiple Sclerosis Market is segmented into Interferons, Immunomodulators, Immunosuppressants, and Others.

Treatment Insights

On the basis of Treatment, Multiple Sclerosis Market is segmented into Physical Therapy, Medications, Plasma Exchange, and Stem Cell Therapy.

End-Users Insights

On the basis of End-Users, Multiple Sclerosis Market is segmented into Specialty Clinics, Homecare, Hospitals, and Others.

Multiple Sclerosis Market Regional Insights:

On region the Multiple Sclerosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period due to rising investment and funding. North America, particularly the United States, has a well-established surgical microscope market with a substantial market size. The presence of advanced healthcare facilities, higher healthcare expenditure, and a demand for cutting-edge medical technologies contribute to market growth.    

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period. The Asia-Pacific region, including countries like China, Japan, and India, represents a rapidly growing market for surgical microscopes. Increasing healthcare expenditure, expanding healthcare infrastructure, and a growing aging population are key factors.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Recent Development:

The New Launched Product News,

  • In March 2021, Johnson & Johnson launched its newly approved drug for adults with relapsing multiple sclerosis (MS) in the United States at a similar price point to rival treatments. A crippling neurological illness known as multiple sclerosis occurs when the immune system attacks the coating that surrounds the nerves. With the clearance, the pharmaceutical company joins a competitive market that is currently controlled by well-known brands like Roche's Ocrevus, Novartis's Kesimpta and Gilenya, and Biogen's best-selling medication Tecfidera.  

 

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 – 2034

Market Segmentation

By Type - Primary progressive MS (PPMS), Secondary progressive MS (SPMS), Clinically isolated syndrome (CIS), and Relapse-remitting MS (RRMS)

By Drug Class - Interferons, Immunomodulators, Immunosuppressants, and Others

By Treatment - Physical Therapy, Medications, Plasma Exchange, and Stem Cell Therapy

By End-Users - Specialty Clinics, Homecare, Hospitals, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 – 2034

Multiple Sclerosis Market Key Players

The key players operating the Multiple Sclerosis Market includes, Pfizer Inc., Bayer AG, AbbVie Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, and Cipla Inc.

Multiple Sclerosis Market Company Profile

  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • F. Hoffmann-La Roche Ltd.  
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company   
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca   
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Cipla Inc.  
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

Multiple Sclerosis Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Treatment
      • Market Snippet, By End-users
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Multiple Sclerosis Market, By Type, Forecast Period up to 10 Years, (US$ Bn)
  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Primary progressive MS (PPMS)
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Secondary progressive MS (SPMS)
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Clinically isolated syndrome (CIS)
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Relapse-remitting MS (RRMS)
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  1. Multiple Sclerosis Market, By Drug Class, Forecast Period up to 10 Years, (US$ Bn)
  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Interferons  
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Immunomodulators
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Immunosuppressants
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  1. Multiple Sclerosis Market, By Treatment, Forecast Period up to 10 Years, (US$ Bn)
  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Physical Therapy
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Medications
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Plasma Exchange
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Stem Cell Therapy
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  1. Multiple Sclerosis Market, By End-Users, Forecast Period up to 10 Years, (US$ Bn)
  • Overview
    • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Specialty Clinics
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Homecare
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Hospitals
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  1. Multiple Sclerosis Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
      • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By End-Users, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By End-Users, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By End-Users, Forecast Period up to 10 Years
      • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By End-Users, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By End-Users, Forecast Period up to 10 Years
    • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis